“Over the past 10 to 15 years, the outcomes of IBD have changed a bit and with those have come some increasing costs of care,” Brad David Constant, assistant professor of pediatric gastroenterology at [CU School of Medicine and] Children’s Hospital Colorado, said at the Crohn’s & Colitis Congress. “These costs of care have been met by the payers and insurance companies to try and make sure that we are not having unnecessary costs in utilization of these medications.”